% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:861622,
      author       = {Galldiks, Norbert and Langen, Karl-Josef},
      title        = {{A}pplications of {PET} imaging of neurological tumors with
                      radiolabeled amino acids},
      journal      = {The quarterly journal of nuclear medicine and molecular
                      imaging},
      volume       = {59},
      number       = {1},
      issn         = {0392-0208},
      address      = {Torino},
      publisher    = {Ed. Minerva Medica},
      reportid     = {FZJ-2019-02068},
      pages        = {70-82},
      year         = {2015},
      abstract     = {Routine diagnostics and treatment monitoring of brain
                      tumors is usually based on contrast-enhanced magnetic
                      resonance imaging (MRI). However, the capacity of structural
                      MRI to differentiate neoplastic tissue from non-specific
                      treatment changes may be limited especially after
                      therapeutic interventions such as neurosurgical resection,
                      radio- and chemotherapy. Metabolic imaging using PET may
                      provide relevant additional information on tumor metabolism,
                      which allows for more accurate diagnostics especially in
                      clinically equivocal situations. In contrast to the widely
                      used ¹⁸F-2-fluoro-2-deoxy-D-glucose, which exhibits a
                      poor tumor-to-background contrast within the brain, amino
                      acid tracers provide high sensitivity to detect primary
                      tumors, recurrent or residual gliomas, including most
                      low-grade gliomas. The method improves targeting of biopsy
                      and provides additional information of tumor extent, which
                      is helpful for planning neurosurgery and radiotherapy. In
                      the further course of the disease, amino acid
                      positron-emission tomography (PET) allows a sensitive
                      monitoring of treatment response, the early detection of
                      tumor recurrence, and an improved differentiation of tumor
                      recurrence from treatment-related changes. In the past, the
                      method had only limited availability due to the use of
                      radiopharmaceuticals with a short half-life. In recent
                      years, however, novel amino acid tracers labeled with
                      positron emitters with a longer half-life have been
                      developed and clinically validated which allow a more
                      efficient and cost-effective application. These developments
                      and the well-documented diagnostic performance of PET using
                      radiolabeled amino acids suggest that its application
                      continues to spread and that the method may be available as
                      a routine diagnostic technique for certain indications in
                      the near future.},
      cin          = {INM-3 / INM-4},
      ddc          = {570},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      url          = {https://juser.fz-juelich.de/record/861622},
}